Delivery Order SPE2DB24D1021-SPE2DB25FEVLK

Award Date 4/1/25
Potential Completion Date 4/2/25
Potential Value $1.2K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award was made by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,433.68 firm fixed-price delivery order contract is for the supply of XCOPRI 100 MG TABLET 30S, a type of pharmaceutical product. The contract has an ultimate completion date of January 9, 2025. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support...
The U.S. government has awarded a Delivery Order contract worth $5,894.80 to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, issued by the Defense Logistics Agency (DLA) Troop Support Medical, is for the supply of the pharmaceutical product XCOPRI 50 MG TABLET 30S. This contract is part of a larger Indefinite Delivery Contract (IDC) valued at $999,999,999 that AmerisourceBergen holds with the DLA, which serves as a primary...
This is a federal contract award from the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $3,071.68, is for the delivery of the drug XCOPRI 50 MG TABLET 30S. The contract type is Delivery Order with a Firm Fixed Price pricing structure, and the ultimate completion date is April 2, 2025. This award is part of a larger Indefinite Delivery Contract (IDC) that Amerisourcebergen holds with the...
This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $5,630.25, is a Delivery Order for the supply of XCOPRI 100 MG TABLET 30S, a medical product. The contract has a firm fixed price and an ultimate completion date of February 18, 2025. This award is part of a larger Indefinite Delivery Contract (IDC) that AmerisourceBergen holds with the DLA Troop...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,768.44 firm-fixed-price contract is for the supply of XCOPRI 100 MG TABLET 30S, a prescription medication. The contract has an ultimate completion date of February 24, 2025. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a primary...
This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract has a ceiling value of $1,768.44 and covers the delivery of the prescription medication XCOPRI 150 MG TABLET 30S. The contract has an ultimate completion date of May 2, 2025. This contract is not set-aside and represents an open competition award. AmerisourceBergen Drug Corp holds a...
This is a $2,357.92 firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the supply of XCOPRI 200 MG TABLET 30S, a medication, to support military treatment facilities, veterans' healthcare programs, and other federal medical institutions. The contract has an ultimate completion date of April 2, 2025. AmerisourceBergen holds a significant...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,178.96 Firm Fixed Price Delivery Order is for the supply of XCOPRI 50 MG TABLET 30S, a pharmaceutical product. The contract has an ultimate completion date of April 10, 2025. Amerisourcebergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,178.96 firm fixed-price delivery order is for the supply of the pharmaceutical product XCOPRI 100 MG TABLET 30S, with a completion date of December 17, 2024. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a primary...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,158.27 firm fixed-price delivery order is for the supply of XCOPRI 100 MG TABLET 30S, a prescription medication. The contract has an ultimate completion date of May 20, 2025 and does not have a set-aside designation, indicating open competition. Amerisourcebergen Drug Corp holds a significant $999,999,999.00...
  • SPE2DB24D1021
    Indefinite Delivery Contract
  • SPE2DB24D1021-SPE2DB25FEVLK
    Delivery Order

This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $1,178.96, is for the supply of the drug XCOPRI 25 MG TABLET 30S. The contract has an ultimate completion date of April 2, 2025.

AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026. This IDC serves as a primary vehicle for providing a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. The company also maintains a separate IDC with the Department of Justice Federal Bureau of Investigation, valued at $750,000 through May 2024, which covers similar medical products and prescription drugs.

The contract award does not have a set-aside designation, indicating open competition.

Generated 7/1/25, 8:15 AM